Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of...
May 05 2015 - 8:05AM
Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology
company focused on developing therapeutic and diagnostic products
for neurological disorders and orphan indications, announced that
it has received a Notice of Allowance from the U.S. Patent and
Trademark Office (USPTO) for U.S. Patent Application Serial No.
13/305,025 entitled, "Dopaminergic Neuronal Survival Promoting
Factors and Uses Thereof." Upon issuance, the patent will provide
additional intellectual property protection for MANF
(mesencephalic-astrocyte-derived neurotrophic factor) protein
therapy and cell therapy. The allowed patent claims cover
compositions of matter and methods of use related to the Company's
proprietary manufacturing process for synthetic MANF and its
administration.
Native MANF is currently under development for the treatment of
orphan ocular indications, including retinitis pigmentosa (RP).
Amarantus recently received orphan drug designation for MANF for
the treatment in RP in the United States and in Europe. In
addition, MANF proteins have demonstrated proof-of-concept in
preclinical models to treat a wide range of conditions including
retinal artery occlusion, glaucoma, macular degeneration,
Parkinson's disease (PD), diabetes and ischemic heart disease,
among others.
"This Notice of Allowance is another important element in our
intellectual property strategy that we believe will allow us to
fully exploit the fundamental value of the research and development
ongoing for MANF, both internally and via our collaborations," said
Gerald E. Commissiong, President & CEO of Amarantus. "MANF is
being developed as a potential therapeutic intervention for orphan
ocular diseases and other chronic disorders for which few, if any,
viable disease-modifying treatment options exist."
"This important step further signals the Company's commitment to
strengthening our industry-leading intellectual property portfolio
surrounding MANF," said John W. Commissiong, Ph.D., Amarantus CSO
and co-discoverer of MANF. "We will continue to strengthen our
robust intellectual property estate to further protect and maintain
our proprietary rights, which we believe will not only allow us to
capitalize on the known opportunities for MANF development, but
will also further entrench Amarantus as the leading company for new
collaborations in light of emerging potential MANF
applications."
The USPTO issues a Notice of Allowance after it makes a
determination that a patent should be granted from a patent
application.
About Mesencephalic-Astrocyte-derived Neurotrophic
Factor (MANF)
MANF (mesencephalic-astrocyte-derived neurotrophic factor) is
believed to have broad potential because it is a
naturally-occurring protein produced by the body for the purpose of
reducing and preventing apoptosis (cell death) in response to
injury or disease, via the unfolded protein response. By
manufacturing MANF and administering it to the body, Amarantus is
seeking to use a regenerative medicine approach to assist the body
with higher quantities of MANF when needed. Amarantus is the
front-runner and primary holder of intellectual property around
MANF, and is initially focusing on the development of MANF-based
protein therapeutics. MANF, a naturally-occurring protein that
reduces and prevents apoptosis (programmed cell death) in response
to injury or disease, was discovered utilizing Amarantus'
proprietary PhenoGuard™ Protein Discovery Engine.
MANF's lead indication is retinitis pigmentosa, and additional
indications including Parkinson's disease, diabetes and Wolfram's
syndrome are currently pursued. Further applications for MANF may
include Alzheimer's disease, traumatic brain injury, myocardial
infarction, antibiotic-induced ototoxicity and certain other rare
orphan diseases currently under evaluation.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases in the areas of
neurology, psychiatry, ophthalmology and regenerative medicine.
AMBS' Therapeutics division has development rights to eltoprazine,
a Phase 2b ready small molecule indicated for Parkinson's disease
levodopa-induced dyskinesia, adult ADHD and Alzheimer's aggression,
and owns intellectual property rights to a therapeutic protein
known as mesencephalic-astrocyte-derived neurotrophic factor (MANF)
and is developing MANF-based products as treatments for brain and
ophthalmic disorders. AMBS' Diagnostics division owns the rights to
MSPrecise®, a proprietary next-generation DNA sequencing (NGS)
assay for the identification of patients with relapsing-remitting
multiple sclerosis (RRMS) at first clinical presentation, and owns
intellectual property for the diagnosis of Parkinson's disease
(NuroPro). AMBS also owns the discovery of neurotrophic factors
(PhenoGuard™) that led to MANF's discovery.
For further information please visit www.Amarantus.com, or
connect with the Company on Facebook, LinkedIn, Twitter and
Google+.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
CONTACT: Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024